Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Indux

Executive Summary

Approval of long bone fracture healing indication for recombinant bone morphogenic protein expected by early 2002, American Home Products CEO Robert Essner tells analysts May 16. Indux (BMP-2) is in Phase III for three indications: long bone fracture, spinal fusion (with Medtronic/Sofamor Danek) and dental craniofacial use. In Phase III trials, standard care of a tibia fracture healed in 20 weeks, while standard care with Indux healed in 14 weeks with more complete bone fusion. Indux sales are expected to reach $500 mil. by 2004, Essner says
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS037888

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel